Research programme: respiratory syncytial virus fusion inhibitors - Panacos Pharmaceuticals

Drug Profile

Research programme: respiratory syncytial virus fusion inhibitors - Panacos Pharmaceuticals

Alternative Names: RSV fusion inhibitors - Panacos Pharmaceuticals

Latest Information Update: 15 Apr 2008

Price : $50

At a glance

  • Originator Panacos Pharmaceuticals Inc
  • Class Small molecules
  • Mechanism of Action Viral fusion protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Respiratory syncytial virus infections

Most Recent Events

  • 15 Mar 2005 Panacos Pharmaceuticals has been acquired and merged into V.I. Technologies
  • 30 Aug 2002 Preclinical trials in Respiratory syncytial virus infections in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top